DTM™ SCS endurance therapy Spinal cord stimulation
DTM™ SCS endurance therapy is a spinal cord stimulation (SCS) therapy available to treat patients with chronic, intractable pain.
Download clinical resultsInspired by science
DTM™ SCS therapy options are inspired by decades of basic science research and preclinical understanding. In a preclinical study, the DTM™ programming (DTMP) derivatives modulated neuro-inflammatory processes more than low-rate SCS.*2
Clinical results show meaningful pain relief
Study objectives
DTM™ SCS endurance therapy study is a prospective, multicenter, single-arm study designed to evaluate the long-term efficacy and energy use of DTM™ SCS endurance therapy.1
Primary objective: To evaluate the effectiveness of DTM™ SCS endurance therapy in reducing overall pain intensity at 3-months follow up.
Secondary objectives with follow up to 12-months:
- Characterize changes in pain intensity for overall, back, and leg pain
- Characterize programming parameters associated with energy use
- Characterize changes in functional disability as measured by Oswestry disability index (ODI)
- Characterize subject satisfaction
- Characterize therapy safety data
Study outcomes
Meaningful
pain relief
4.1
reduction in VAS for overall pain
from baseline to 6 months1
Meaningful and sustained pain relief at 6 months1
Meaningful quality of
life improvements
63%
of patients had minimal to moderate disability
at 3 months compared to only 16% at baseline1
Therapy satisfaction
75%
of patients are very or somewhat
satisfied with therapy1
Long lasting
5½-7½
years of recharge-free longevity
estimated using actual 6-month
programming data3
Save time
5 minutes
estimated daily rapid recharge
or recharge less frequently
(1 hour every 12 days)3
Superior
pain relief
DTM™ SCS offers proven pain relief backed by data on Intellis™ SCS. Learn about the therapy.4
See DTM™ SCSVanta™ SCS neurostimulator
High performance and recharge free. Experience DTM™ SCS endurance therapy on Vanta™.
Intellis™ SCS neurostimulator
Rapid recharge available with DTM™ SCS or DTM™ SCS endurance therapy.
See the device manual for detailed information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events. If using an MRI SureScan® device, see the MRI SureScan® technical manual before performing an MRI. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.eu.
For applicable products, consult instructions for use on www.medtronic.com/manuals. Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser.
*Note: Data obtained from animal studies should not be extrapolated to clinical/human results.
1
Peacock, Provenzano, Fishman, et al. A prospective multi-center study of a differential target multiplexed™ stimulation derivative in therapy-naive patients. Poster presented at: International Neuromodulation Society (INS) World Congress; May 21-26, 2022; Barcelona, Spain.
2
Cedeno D, Vallejo R, Platt D, et al. Differential target multiplexed SCS using reduced energy parameters in an animal model of neuropathic pain. Poster presented at: American Society of Pain and Neuroscience (ASPN) annual meeting. July 22-25, 2021.
3
Provenzano, Amirdelfan, Grewal, et al. Modeling the impact of a differential target multiplexed derivative on rechargeable and recharge-free spinal cord stimulation systems using results from the Endurance Study. Poster presented at: International Neuromodulation Society (INS) World Congress; May 21-26, 2022; Barcelona, Spain.
4
Fishman M, Cordner H, Justiz R, et al. 12-Month Results from Multicenter, Open-Label, Randomized Controlled Clinical Trial Comparing Differential Target Multiplexed Spinal Cord Stimulation and Traditional Spinal Cord Stimulation in Subjects with Chronic Intractable Back Pain and Leg Pain. Pain Pract. 2021; 21: 912– 923.